Key Takeaways
- 571 patients in the PANOVA-3 trial.
- Pain worsening delayed: 10.1 vs 7.4 months.
- Device worn 18+ hours a day.
For This Cancer, Time Without Pain Is the Prize
For someone living with pancreatic cancer, another month matters. Another month without worsening pain matters even more.
A new analysis of the PANOVA-3 trial, published in JAMA Network Open, reports exactly that kind of victory. The trial randomized 571 patients with unresectable, locally advanced pancreatic cancer to standard chemotherapy (gemcitabine plus nab-paclitaxel), either alone or combined with Tumor Treating Fields.
Tumor Treating Fields is a portable device, Novocure's NovoTTF-200T, that delivers low-intensity electric fields through skin patches to disrupt cancer-cell division. Patients wore the device for at least 18 hours a day.
What the numbers say
Patients on the device kept their pain at bay significantly longer. Median time to pain deterioration was 10.1 months with the device, compared with 7.4 months with chemotherapy alone.
For pancreatic pain specifically, the difference was even larger: 14.7 versus 10.2 months. Patients also went longer before needing opioids: 9.3 months compared with 6.7 months.
Overall quality-of-life scores remained stable in both groups. The device added mainly skin irritation rather than systemic side effects.
The trial's primary analysis, reported earlier, also found a survival edge: median overall survival was 16.2 months with the device versus 14.2 months with chemotherapy alone.
The honesty beat
This latest paper is a secondary quality-of-life analysis, not the trial's main report. The study was open-label, meaning patients knew whether they were wearing the device. That matters because knowing which treatment you're receiving can influence how you report pain and quality of life.
The opioid finding was also a post-hoc analysis, and Novocure, the device's manufacturer, designed the trial. The results are encouraging, but independent confirmation matters before drawing stronger conclusions.
Health note: Tumor Treating Fields is a prescribed, specialist-managed treatment. If you or a family member is facing locally advanced pancreatic cancer, ask the oncology team whether this treatment is available and appropriate for your situation.
The Twikup Take
Two extra months of survival made the first headlines. But for patients in this trial, nearly three extra months before pain deteriorated could be a meaningful victory. It is the outcome they actually reported.
Image: Illustrative image.